Loomis Sayles & Co. L P trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 6.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,671,011 shares of the company's stock after selling 241,194 shares during the quarter. Loomis Sayles & Co. L P owned 0.50% of Roivant Sciences worth $43,428,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its stake in shares of Roivant Sciences by 30.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,767,412 shares of the company's stock worth $31,936,000 after buying an additional 646,627 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Roivant Sciences by 10.8% in the third quarter. The Manufacturers Life Insurance Company now owns 356,600 shares of the company's stock valued at $4,115,000 after acquiring an additional 34,641 shares during the period. FMR LLC boosted its position in Roivant Sciences by 5.6% in the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock worth $567,134,000 after purchasing an additional 2,593,910 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Roivant Sciences by 26.3% during the 3rd quarter. MetLife Investment Management LLC now owns 225,320 shares of the company's stock worth $2,600,000 after purchasing an additional 46,879 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Roivant Sciences by 49.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company's stock valued at $26,625,000 after purchasing an additional 762,953 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

In related news, COO Eric Venker sold 177,704 shares of the business's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16. Following the transaction, the chief operating officer now directly owns 740,976 shares in the company, valued at approximately $8,550,863.04. The trade was a 19.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were acquired at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 1,573,245 shares of company stock valued at $17,079,242 over the last ninety days. Insiders own 7.90% of the company's stock.

Several research firms recently commented on ROIV. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of "Buy" and an average price target of $17.10.

Read Our Latest Stock Report on ROIV

Shares of NASDAQ ROIV opened at $10.48 on Friday. The firm has a market cap of $7.48 billion, a price-to-earnings ratio of -69.86 and a beta of 1.26. The company's 50-day simple moving average is $10.76 and its 200-day simple moving average is $11.43. Roivant Sciences Ltd. has a 52-week low of $9.96 and a 52-week high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

(Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Roivant Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.

While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here